Company Press Releases 1.11.12CytoSorbents 2011 End of Year Shareholder Letter 12.14.11CytoSorbents Awarded US Army SBIR Trauma Grant 12.09.11CytoSorbents Announces Purchase Agreement for up to $8.5 Million With Lincoln Park Capital 11.15.11CytoSorbents Corporation Reports Third Quarter 2011 Financial Results and Corporate Update 10.25.11CytoSorbents Corporation to Present at the IN3 Medical Device Summit 10.17.11CytoSorbents Corporation Launches HemoDefend Purification Technology Platform for Blood Transfusion Applications at the AABB Conference CTTXPO Exhibition 9.23.11CytoSorbents Corporation to Exhibit at the European Society of Intensive Care Medicine Congress in Berlin and at the AdvaMed Conference in Washington D.C. 9.13.11CytoSorbents Announces New Statistical Analysis and Confirms Statistical Significance in 28-Day Mortality 9.8.11CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference 9.7.11CytoSorbents Corporation Announces Additional Data From European Sepsis Trial 9.1.11CytoSorbents Corporation to Exhibit at the German Sepsis Society International Congress 8.16.11CytoSorbents Corporation Reports Second Quarter 2011 Financial Results 8.4.11CytoSorbents Corporation to Exhibit at the Advanced Technology Applications for Combat Casualty Care Conference 6.6.11CytoSorbents Corporation Releases Shareholder Letter 3.31.11CytoSorbents Corporation Achieves European Union Regulatory Approval for CytoSorb™ 2.22.11CytoSorbents Closes Convertible Note With Additional $1.25 Million Raised 02.17.11CytoSorbents Corporation Broadens Its Intellectual Property Portfolio 12.30.10CytoSorbents Corporation to Present at the OneMedForum 2011 Finance Conference 11.17.10CytoSorbents Corporation Reports Third Quarter 2010 Financial Results 11.2.10CytoSorbents Corporation Awarded $488,958 Grant from the Federal Qualifying Therapeutic Discovery Project Program 09.27.10CytoSorbents Corporation Achieves ISO 13485 Certification 09.09.10CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference 09.01.10CytoSorbents' Chief Financial Officer is named a finalist for '2010 CFO of the Year' award by NJBIZ 08.19.10CytoSorbents Corporation Reports Second Quarter 2010 Financial Results 08.11.10CytoSorbents Corporation to Present Today at the Emerging Medical Technologies Spotlight Online Conference 07.26.10CytoSorbents Corporation to Exhibit at the Force Health Protection Conference and ATACCC 06.08.10CytoSorbents Corporation to Present at the In3 East Medical Device Conference 05.24.10CytoSorbents Corporation to Present at BioNJ BioPartnering Conference 05.17.10CytoSorbents Corporation Reports First Quarter 2010 Financial Results 05.10.10Cytosorbents Corporation Enters Into Funding Agreement 05.06.10 MedaSorb Technologies Announces Company Name Change to CytoSorbents Corporation 04.12.10 MedaSorb Technologies Corporation Reports Full Year 2009 Financial Results 02.17.10 MedaSorb Technologies Corporation Improves Cash Position and Hits Midway Point in Study Enrollment 01.11.10MedaSorb Technologies Corporation to Present at the Biotech Showcase™ 2010 11.13.09MedaSorb Technologies Corporation Provides Clinical Update 11.13.09MedaSorb Technologies Corporation Announces Q3 2009 Results and Files Form 10-Q, Quarterly Report 8.18.09MedaSorb Technologies Corporation to Present at the Rodman & Renshaw Global Investment Conference 7.16.09MedaSorb and CytoSorbents CEO Featured in Interviews by The Wall Street Transcript and CEO-CFO Interviews 5.06.09 CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak 3.30.09 CytoSorbents, Inc. Recognized as "Company Most Likely to Succeed" at the 2009 New Jersey Venture Conference and Provides Clinical Update 2.03.09 MedaSorb Technologies Corporation Improves Balance Sheet 1.9.09 MedaSorb Technologies Corporation Announces Management Changes August 2008 Letter To Our Shareholders 1.4.07 MedaSorb Announces IDE Filing with the FDA 11.3.06 MedaSorb Technologies Corporation Files New Patent Application 10.27.06 MedaSorb Technologies Adds Strategic Technology Patent 9.19.06 MedaSorb Announces That They Intend to File Investigational Device Exemption With the FDA 8.7.06 MedaSorb Technologies to Begin Trading under the Symbol MSBT 7.25.06 Gilder Enterprises, Inc. Acquires MedaSorb Corporation and Raises $5.25 Million
Publications